, also called urokinase-type plasminogen activator (uPA), is a serine protease (EC 3.4.21.73). Urokinase was originally isolated from human urine, but is present in several physiological locations, such as blood stream and the extracellular matrix. It is a kind of bulk pharmaceutical chemical. There are some basic informations about this crude drug: (1)CAS No.: ; (2)Other Names: Urokinase; (3)ATC code B01AD04; (4)DrugBank BTD00030; (5)KEGG D03341; (6)Formula: C₁₃₇₆H₂₁₄₅N₃₈₃O₄₀₆S₁₈; (7)Mol. mass: 31126.5 g/mol.

Urokinase is used clinically as a thrombolytic agent in the treatment of severe or massive deep venous thrombosis, pulmonary embolism, myocardial infarction, and occluded intravenous or dialysis cannulas. It is also administered intrapleurally to improve the drainage of complicated pleural effusions and empyemas. Urokinase is presently marketed as KinlyticTM, and competes with AlteplaseTM as a thrombolytic drug in infarctation.